1. Scrip
  3. >>Earnings

Xarelto Still Climbs As Bayer Touts Successor

Strong Q4 For Pharma Division

 
• By Kevin Grogan

Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.

Bayer cross
• Source: Bayer

Bayer AG has posted a healthy set of financials for the fourth quarter with its pharmaceuticals division continuing to recover from the effects of COVID 19 and make progress with the pipeline, notably with a potential successor to its current bestseller product Xarelto.

Pharma revenues in the quarter were up by 7.6% (currency adjusted) to €4.95bn and the division's chief Stefan Oelrich told journalists at Bayer's annual press conference on 1 March that sales of a number of treatments, particularly in the areas of ophthalmology, women’s healthcare and radiology, rose sharply

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business